The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Complement C5 inhibition is the standard of care for symptomatic paroxysmal nocturnal hemoglobinuria (PNH).
• Current C5 inhibitors require intravenous administration due to challenges in drug development, limiting patient convenience.
• Crovalimab is a novel monoclonal antibody engineered for subcutaneous delivery.

Purpose of the Study:

• To assess the safety, pharmacokinetics, pharmacodynamics, and exploratory efficacy of crovalimab in healthy volunteers and PNH patients.
• To evaluate crovalimab's ability to achieve sustained terminal complement pathway inhibition.
• To determine the feasibility of self-administered subcutaneous dosing for PNH treatment.

Main Methods:

• A 3-part open-label adaptive phase 1/2 trial was conducted.
• Participants included healthy volunteers, complement blockade-naive PNH patients, and C5 inhibitor-pretreated PNH patients.
• Safety, pharmacokinetics, pharmacodynamics, and exploratory efficacy were assessed.

Main Results:

• Crovalimab achieved complete and sustained terminal complement pathway inhibition in PNH patients.
• Hemolytic activity and free C5 levels were suppressed below clinically relevant thresholds.
• Subcutaneous crovalimab (680 mg every 4 weeks) demonstrated a favorable safety profile consistent with C5 inhibition, with transient skin reactions in 2/19 patients.

Conclusions:

• Subcutaneous crovalimab provides complete and sustained terminal complement pathway inhibition in PNH patients.
• The drug is suitable for self-administration, offering a convenient alternative to IV treatments.
• Crovalimab warrants further clinical development for PNH management.